{"nctId":"NCT01198327","briefTitle":"Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion","startDateStruct":{"date":"2010-08"},"conditions":["Retinal Vein Occlusion"],"count":66,"armGroups":[{"label":"Ranibizumab as needed","type":"EXPERIMENTAL","interventionNames":["Drug: ranibizumab","Other: Peripheral Laser"]}],"interventions":[{"name":"ranibizumab","otherNames":["RBZ, lucentis"]},{"name":"Peripheral Laser","otherNames":["Laser"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent and authorization of use and disclosure of protected health information\n* Age greater than or equal to 18 years\n* Completion of 12 months in BRAVO or CRUISE trials, with subsequent follow-up in the HORIZON extension study. Exit from HORIZON should be within 90 days of enrollment\n\nExclusion Criteria:\n\n* Pregnancy (positive pregnancy test) or lactation\n* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.\n* Any condition that the investigator believes would pose a significant hazard to the subject if investigational therapy were initiated.\n* Inability to comply with study or follow up procedures\n* Participation in another simultaneous medical investigation or trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Serious Adverse Events.","description":"Record the serious adverse events, both ocular and non-ocular to gather long-term safety data.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Changes in Visual Acuity","description":"Mean changes in visual acuity. Visual acuity is measured using standard ETDRS (Early Treatment Diabetic Retinopathy Study) charts which measure visual acuity in terms of letters( ETDRS Letters) read at a distance of 4 meters away from the chart. The ETDRS letters Score can be from 0 to 100, with 0 representing poor vision and 100 representing best vision.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"20.9"},{"groupId":"OG001","value":"20.1","spread":"17.2"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Retinal Thickness","description":"Mean change in retinal thickness as measured by OCT (Optical Coherence Tomography).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-426.0","spread":"270.1"},{"groupId":"OG001","value":"-236.2","spread":"230.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":66},"commonTop":["Upper Respiratory Infection","Ocular discomfort","Subconjuctival Hemorrhage","Vitreous Hemmorhage"]}}}